Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

This study is testing a combination of two targeted drugs — zanubrutinib (a BTK inhibitor that blocks a protein cancer cells use to grow) and tafasitamab (an antibody that targets the CD19 protein on cancer cells) — for patients with mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma. The study has two phases: one for relapsed patients and one for newly diagnosed patients who are not eligible for intensive chemotherapy. **You may be eligible if...** - You are 18 or older with confirmed mantle cell lymphoma - Phase 1: Your MCL has relapsed after 1–3 prior treatments - Phase 2: You have newly diagnosed MCL that your doctor does not think is suitable for aggressive chemotherapy - Your blood counts and organ function meet the minimum requirements **You may NOT be eligible if...** - You have lymphoma that has spread to the brain - You have serious heart problems (including QTc prolongation or recent heart attack) - You are pregnant or breastfeeding - You have active hepatitis B or C infection - You have had a prior bone marrow transplant from a donor Talk to your doctor to see if this trial is right for you.